News

Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors

Featured Press Release, Milestone, News, Press Releases, Uncategorized / By

SINGAPORE and UNITED STATES — 22 JULY 2026 — Tikva Allocell today announced the successful closing of an $8 million Series A financing round, led by Kantharos Capital. The capital will accelerate the development of Tikva’s novel off-the-shelf, engineered allogeneic T-cell platform designed to tackle persistent challenges in solid tumor oncology. The funding will primarily support …

Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors Read More »

The multifarious role of SerpinB9 armoring

Featured Publications, Publications / By

CAR-T cell therapy has revolutionized cancer treatment, but its efficacy against solid tumors remains limited due to challenges like poor CAR-T cell in-vivo survival. Tikva’s engineered SB9 EBVST platform will not only address a major resistance mechanism axis but also opens doors to more effective CAR T cell therapies for solid tumors.

Tikva published paper on Novel OX40 and 4-1BB Derived Spacers Enhance CD30 CAR Activity and Safety in CD30 Positive Lymphoma Models

Leave a Comment / Featured Publications, News, Press Releases, Publications / By

SINGAPORE – 8 Jul 2024 – Tikva Allocell Scientists published scientific article in Cell Molecular Therapy on Novel OX40 and 4-1BB Derived Spacers Enhance CD30 CAR Activity and Safety in CD30 Positive Lymphoma Models. The chimeric antigen receptor is made up of several domain, all of which have important roles to play in determining the …

Tikva published paper on Novel OX40 and 4-1BB Derived Spacers Enhance CD30 CAR Activity and Safety in CD30 Positive Lymphoma Models Read More »